Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 4/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | AGXT | P21549 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075637 | 0.87 | LOXL2 (0.69) | LOXL2HTR2BHTR1AAGXTSLC5A2 | |
| SCHEMBL11107879 | 0.87 | LOXL2 (0.55) | LOXL2HTR2BHTR1AAGXTDRD2 | |
| SCHEMBL11616186 | 0.85 | LOXL2 (0.53) | LOXL2HTR2BHTR1AAGXTDRD2 | |
| SCHEMBL16429505 | 0.85 | CYP11B1 (0.63) | LOXL2HTR2BHTR1AAGXTSLC5A2 | |
| SCHEMBL29087527 | 0.85 | LOXL2 (0.53) | LOXL2HTR2BHTR1AAGXTDRD2 | |
| SCHEMBL10368738 | 0.85 | LOXL2 (0.53) | LOXL2HTR2BHTR1AAGXTDRD2 | |
| SCHEMBL11612003 | 0.85 | LOXL2 (0.53) | LOXL2HTR2BHTR1AAGXTDRD2 | |
| SCHEMBL26445730 | 0.83 | LOXL2 (0.55) | LOXL2HTR2BHTR1AAGXTDRD2 | |
| SCHEMBL154626 | 0.83 | MAOB (0.51) | LOXL2HTR2BHTR1AAGXTDRD2 | |
| SCHEMBL24400607 | 0.82 | PPARG (0.60) | LOXL2HTR2BHTR1AAGXTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119264201-A | 2-Benzyl benzofuran and diaryl acetone compounds or pharmaceutically acceptable salts thereof and application thereof | 北京振东光明药物研究院有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-112675919-B | Application of N-heterocyclic carbene-based mixed nickel (II) complex in synthesis of alpha-benzyl benzofuran compound | 苏州大学 | 2023-06-13 | — | — | CN | claimed |
| CN-119264201-A | 2-Benzyl benzofuran and diaryl acetone compounds or pharmaceutically acceptable salts thereof and application thereof | 北京振东光明药物研究院有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-119264201-A | 2-Benzyl benzofuran and diaryl acetone compounds or pharmaceutically acceptable salts thereof and application thereof | 北京振东光明药物研究院有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-119264201-A | 2-Benzyl benzofuran and diaryl acetone compounds or pharmaceutically acceptable salts thereof and application thereof | 北京振东光明药物研究院有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-112675919-B | Application of N-heterocyclic carbene-based mixed nickel (II) complex in synthesis of alpha-benzyl benzofuran compound | 苏州大学 | 2023-06-13 | — | — | CN | disclosed |
| US-10918624-B2 | Anti-cancer azole compounds | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2021-02-16 | — | — | US | disclosed |
| US-20200375952-A1 | ANTI-CANCER AZOLE COMPOUNDS | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2020-12-03 | — | — | US | disclosed |
| US-9233362-B2 | Molybdenum and tungsten metal complexes and use thereof as precatalysts for olefin metathesis | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2016-01-12 | — | — | US | disclosed |
| US-9233362-B2 | Molybdenum and tungsten metal complexes and use thereof as precatalysts for olefin metathesis | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2016-01-12 | — | — | US | disclosed |
| US-9233362-B2 | Molybdenum and tungsten metal complexes and use thereof as precatalysts for olefin metathesis | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2016-01-12 | — | — | US | disclosed |
| EP-0295851-A1 | 4,7-diacyloxybenzofuran derivatives | MERCK FROSST CANADA INC. (CA) | 1988-12-21 | — | — | EP | disclosed |
| US-4778805-A | ANTIALLERGENS, CARDIOVASCULAR DISORDERS, ANTIINFLAMMATORY AGENTS, SKIN AND VISION DISORDERS | MERCK FROSST CANADA (CA) | 1988-10-18 | — | — | US | disclosed |
| EP-0165810-A2 | Benzofuran and benzothiophene derivatives, their use in inhibiting mammalian leukotriene biosynthesis, and pharmaceutical compositions containing these derivatives | MERCK FROSST CANADA INC. (CA) | 1985-12-27 | — | — | EP | disclosed |
| US-4117128-A | SULFONYL BENZOFURANS AND BENZOTHIOPHENES HAVING CORONARY VASODILATOR ACTIVITY | SMITHKLINE CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4024273-A | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity | SMITHKLINE CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-4001426-A | HAVING CORONARY VASODILATOR ACTIVITY | SMITHKLINE CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-3983245-A | CORONARY VASODILATORS | SMITHKLINE CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
| US-3975537-A | SUBSTITUTED BENZOFURANS | SMITH KLINE (US) | 1976-08-17 | — | — | US | disclosed |
| US-3947470-A | CORONARY VASODILATORS, TREATMENT OF ANGINA PECTORIS | SMITHKLINE CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200375952-A1 | ANTI-CANCER AZOLE COMPOUNDS | RB1, API5, TP53 | LOXL2 4558/4885HTR2B 4277/4885HTR1A 4704/4885 |
| US-10918624-B2 | Anti-cancer azole compounds | RB1, API5, TP53 | LOXL2 4558/4885HTR2B 4277/4885HTR1A 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.